Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With
Epigenetic Evaluation of HAT/HDAC Activity in Peripheral Blood Mononuclear Cells From Patients With Clinically Isolated Syndrome and Analysis of the Relationship With the Pathophysiology and Disease Activity
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- blood sample
What it measured
Main measures
HDAC/ HAT enzymatic activity (ratio)
day of inclusion
Who could take part
Early (CIS/RIS) · 18 to 60
Show the full criteria
Inclusion criteria
* Clinically isolated syndrome within the last 6 weeks (CIS group) * Healthy volunteer, free of any inflammatory disease (control group) * Patient able to understand the reason of the study * Signed informed consent
Exclusion criteria
* Pregnancy * Systemic corticosteroid therapy (>1mg/kg) * Immunosuppressive/immunomodulatory therapy (prior or ongoing) (CIS group) * Patient with ongoing infection (Control group)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of the study is to compare the enzymatic activity of HATs and HDACs in peripheral blood mononuclear cell (PBMC) of patients with a clinically isolated syndrome (CIS group) and healthy controls (control group).
Loading reviews and guidelines…
History
Started
Apr 2016
Main results due
Jun 2020
Finished
Sept 2020